RenovoRx announced the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for treating bile duct cancer, also known as cholangiocarcinoma, with intra-arterial gemcitabine. The Company's proprietary FDA cleared medical device system, RenovoCath?, employs a dual-balloon infusion catheter, enabling the Trans-Arterial Micro-Perfusion (TAMPTM) approach for targeted delivery of gemcitabine to the tumor site.

In April 2018, RenovoRx received FDA orphan drug designation for treatment of pancreatic cancer with intra-arterial gemcitabine. RenovoRx's proprietary TAMP delivery of gemcitabine is being utilized in the TIGeR-PaC Phase III trial evaluating extended median survival and improved Quality of Life for pancreatic cancer patients.

In the United States, more than 8,000 people develop cholangiocarcinoma annually. However, research suggests the incidence is higher due to misdiagnosis. The disease is nearly five times more common in Asia and the Mideast, largely due to parasitic liver fluke infections.

"Receiving a second orphan drug designation from the FDA is a significant milestone as we build the TAMP platform for solid tumor treatment.  This new orphan drug indication builds on the momentum of the TIGeR-PaC Phase III clinical trial currently treating pancreatic cancer patients in the U.S. and Europe," said RenovoRx CEO Shaun Bagai. "To help bile duct cancer patients, we are designing a Phase I/II clinical trial that will launch by early next year. This expansion of the RenovoRx platform, beyond pancreatic cancer, could improve outcomes for more cancer patients."

The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for underserved patient populations, or rare disorders, affecting fewer than 200,000 people in the U.S. Orphan drug designation provides RenovoRx certain benefits, including market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials.